Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rang in Aktien #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Aktienkurs
$1.51
Zuletzt synchronisiert: 2024-08-26
Marktkapitalisierung
$1.12M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Agile Therapeutics, Inc. (AGRX)

Kategorie

P/B-Verhältnis für Agile Therapeutics, Inc. (AGRX)
P/B-Verhältnis zum August 2026 TTM: -0.20
Laut den neuesten Finanzberichten und dem Aktienkurs von Agile Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) -0.20. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei -0.88.
P/B-Verlauf für Agile Therapeutics, Inc. von 2012 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) -0.20 -23.23%
2023 -0.26 -70.87%
2022 -0.88 -792.80%
2021 0.13 -97.41%
2020 4.93 82.38%
2019 2.70 175.75%
2018 0.98 -57.24%
2017 2.29 -39.87%
2016 3.81 -47.25%
2015 7.22 271.82%
2014 1.94 -377.53%
2013 -0.70 -17.96%
2012 -0.85 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber